Andrey Sudarikov

Dr. Andrey Sudarikov

Molecular Hematology, National Medical Research Center for Hematology, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2021 in Blood
Verified
Journal Article
Open access
PDF file
AAAndreas Agathangelidis
Andreas Agathangelidis
ACAnastasia Chatzidimitriou
Anastasia Chatzidimitriou
KGKaterina Gemenetzi
Katerina Gemenetzi
VGVéronique Giudicelli
Véronique Giudicelli
MKMaria Karypidou
Maria Karypidou
KSKostas Stamatopoulos
Kostas Stamatopoulos
Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR immunoglobulin stereotypy in CLL has important implications for understanding disease pathophysiology and refining clinical decision-making. Nevertheless, several issues remain open, especially pertaining to the actual frequency of BcR immunoglobulin stereotypy and major subsets, as well as the existence of higher-order connections between individual subsets. To address these issues, we investigated clonotypic IGHV-IGHD-IGHJ gene rearrangements in a series of 29 856 patients with CLL, by far the largest series worldwide. We report that the stereotyped fraction of CLL peaks at 41% of the entire cohort and that all 19 previously identified major subsets retained their relative size and ranking, while 10 new ones emerged; overall, major stereotyped subsets had a cumulative frequency of 13.5%. Higher-level relationships were evident between subsets, particularly for major stereotyped subsets with unmutated IGHV genes (U-CLL), for which close relations with other subsets, termed “satellites,” were identified. Satellite subsets accounted for 3% of the entire cohort. These results confirm our previous notion that major subsets can be robustly identified and are consistent in relative size, hence representing distinct disease variants amenable to compartmentalized research with the potential of overcoming the pronounced heterogeneity of CLL. Furthermore, the existence of satellite subsets reveals a novel aspect of repertoire restriction with implications for refined molecular classification of CLL.

1 October 2004 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
MKMarina Konopleva
Marina Konopleva
EEElena Elstner
Elena Elstner
TMTeresa J. McQueen
Teresa J. McQueen
TTTwee Tsao
Twee Tsao
ASAndrey Sudarikov
Andrey Sudarikov
MAMichael Andreeff
Michael Andreeff
The peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear receptor family that forms heterodimers with retinoid X receptor. These heterodimers bind to DNA and activate the transcription of target genes. Here, we report that the PPARγ receptor protein is expressed in primary myeloid and lymphoid leukemias and in lymphoma and myeloma cell lines. In this study, we compared the activity of several PPARγ ligands including BRL49653 (rosiglitazone), 15-deoxy-Δ12,14-prostaglandin J2, and the novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid on leukemia cells. Exposure to these PPARγ ligands induced apoptosis in myeloid (U937 and HL-60) and lymphoid (Su-DHL, Sup-M2, Ramos, Raji, Hodgkin's cell lines, and primary chronic lymphocytic leukemia) cells. A similar exposure to these PPARγ ligands induced the differentiation of myeloid leukemic cells. A combination of PPARγ ligands with a retinoid X receptor agonist (i.e., LG100268) or a retinoic acid receptor agonist (i.e., all trans-retinoic acid) enhanced differentiating and growth-inhibitory effects. 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid induced differentiation and apoptosis with much greater potency than the other PPARγ ligands in established cell lines and primary chronic lymphocytic leukemia samples. Exposure to 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induced mitochondrial depolarization and caspase activation, which was associated with apoptosis induction. In Bcl-2-overexpressing chronic lymphocytic leukemia cells, the small-molecule Bcl-2 inhibitor HA14-1 sensitized these cells to 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid–induced apoptosis. These results suggest that PPARγ ligation alone and in combination with retinoids holds promise as novel therapy for leukemias by activating the transcriptional activity of target genes that control apoptosis and differentiation in leukemias.

5 December 2007 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
OGOlga A. Gra
Olga A. Gra
Andrey Sergeevich GlotovAndrey Sergeevich Glotov
Andrey Sergeevich Glotov
ENEugene Nikitin
Eugene Nikitin
OGOleg Glotov
Oleg Glotov
VKViktoria E. Kuznetsova
Viktoria E. Kuznetsova
TNTatyana V. Nasedkina
Tatyana V. Nasedkina
Polymorphisms in genes coding xenobiotic‐metabolizing enzymes are considered as risk factors modifying susceptibility to cancer. We developed a biochip for the analysis of 18 mutations in 10 genes of metabolizing system: CYP1A1, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, CYP2C9, CYP2C19, and NAT2. Using allele‐specific hybridization on the biochip 76 T‐cell non‐Hodgkin's lymphoma (NHL) patients, 83 B‐cell chronic lymphocytic leukemia (B‐CLL) patients, and 177 healthy donors were tested. Polymorphic CYP1A1 alleles were more frequent in B‐CLL patients relative to normal controls, for example, a combination of polymorphic variants 4887C > A, 4889A > G, and 6235T > C (OR = 1.76, 95% CI = 1.0–3.1). The GSTM1 null genotype was more frequent in NHL patients relative to controls (OR = 1.82, 95% CI = 1.1–3.1). The combination of unfavorable polymorphic CYP1A1 variants and GSTM1 null genotype was found more frequently in B‐CLL patients relative to controls (OR = 2.52, 95% CI = 1.3–4.9). In addition, male B‐CLL patients demonstrated a significantly increased occurrence of heterozygous and homozygous allele *2 of CYP2C9 gene (OR = 2.38, 95% CI = 1.1–5.2) as well as a combination of alleles *2 and *3 of the gene (OR = 2.09, 95% CI = 1.1–3.9). Thus, our findings show the association between polymorphic alleles of CYP1A1, GSTM1, and CYP2C9 genes and the risk to develop NHL or B‐CLL. The developed biochip can be considered as a convenient analytical tool for research studies and predictive analysis in oncohematology. Am. J. Hematol., 2008.

1 September 2001 in Physics of Atomic Nuclei
Verified
Journal Article
Closed access
PDF file
KBK. M. Belotsky
K. M. Belotsky
ASAndrey Sudarikov
Andrey Sudarikov
MKM. Yu. Khlopov
M. Yu. Khlopov
The features of a hypothetical 4ν interaction considered as the possible reason for massive-neutrino instability required in the cosmological scenario that involve neutrino dark matter are discussed. New constraints on the 4ν-interaction constant G χ are obtained: G χ<(15–42)G F for m χ>G Z (G F is the Fermi constant of weak interaction; m χ is the mass of the 4ν-interaction gauge boson, also known as χ boson; and m Z is the Z-boson mass) and G χ<(2.8–5.6)G F for m χ≪G Z . These constraints virtually rule out the 4ν interaction as a possible version of solution to the cosmological neutrino-instability problem.

31 August 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AXAliki Xochelli
Aliki Xochelli
PBPanagiotis Baliakas
Panagiotis Baliakas
IKIoannis Kavakiotis
Ioannis Kavakiotis
AAAndreas Agathangelidis
Andreas Agathangelidis
LSLesley-Ann Sutton
Lesley-Ann Sutton
KSKostas Stamatopoulos
Kostas Stamatopoulos
Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34–expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P < 0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management. Clin Cancer Res; 23(17); 5292–301. ©2017 AACR.

5 December 2020 in Rheumatology International
Verified
Journal Article
Open access
PDF file
VGVadim Gorodetskiy
Vadim Gorodetskiy
YSYulia Sidorova
Yulia Sidorova
NKNatalia Alexandrovna Kupryshina
Natalia Alexandrovna Kupryshina
VVVladimir Ivanovich Vasilyev
Vladimir Ivanovich Vasilyev
NPNatalya Alexandrovna Probatova
Natalya Alexandrovna Probatova
ASAndrey Sudarikov
Andrey Sudarikov
T-cell large granular lymphocytic leukemia (T-LGLL) is a lymphoproliferative disorder characterized by a persistent increase in the number of large granular lymphocytes (LGLs), neutropenia, and splenomegaly. Clinical manifestations of T-LGLL in the setting of rheumatoid arthritis (RA) are often identical to those in which one would suspect Felty's syndrome (FS). These disorders are distinguished by the presence of T-cell clonality, which is present in T-LGLL but not in FS. Mutations in the signal transducer and activator of transcription 3 (STAT3) and 5b (STAT5b) genes can be used as molecular markers of T-LGLL, but their prevalence in FS is unknown.Eighty-one patients with RA and unexplained neutropenia or/and an increase in the number of LGLs above 2 × 109/L were stratified into RA-associated T-LGLL (N = 56) or FS (N = 25) groups based on the presence or absence of T-cell clonality. STAT3 and STAT5b gene mutations were assessed in each group by means of allele-specific polymerase chain reaction assays. Clinical, immunological, laboratory data and the results of immunophenotyping of blood and bone marrow lymphocytes were also evaluated.Mutations of the STAT3 gene and an increase in the number of LGLs above 2 × 109/L were detected in RA-associated T-LGLL, but not in FS (39% vs 0% and 21% vs 0%, respectively). Mutations in the STAT5b gene were not observed in either group. Expression of CD57, CD16, and CD5−/dim on CD3+CD8+ T-lymphocytes was observed in both RA-associated T-LGLL and FS.STAT3 gene mutations or LGL counts over 2 × 109/L in RA patients are indicative of T-LGLL.